Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals

InnoCare Pharma Partners with Westlake University for Innovative Drug Research

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced a strategic partnership agreement with Westlake...

Company Drug

Betta Pharmaceuticals Secures Macau Approval for Ensartinib

Fineline Cube May 13, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...

Company Deals

OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots

Fineline Cube May 13, 2025

Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...

Company Deals

Genentech to Invest Over $700 Million in North Carolina Drug Manufacturing Facility

Fineline Cube May 13, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest...

Company Drug

Huadong Medicine Presents DR10624 Study Results for Obesity and Hypertriglyceridemia at EASL 2025

Fineline Cube May 13, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its...

Company

Teva Announces 8% Workforce Reduction to Achieve $700 Million Cost-Saving Goal

Fineline Cube May 13, 2025

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has disclosed plans to reduce its workforce by...

Company Deals Drug

Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007

Fineline Cube May 13, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...

Company Deals

Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases

Fineline Cube May 13, 2025

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...

Company Deals

Tenacia Partners with TSH Biopharm for Ztalmy Commercialization in Taiwan

Fineline Cube May 13, 2025

Tenacia Biotechnology, a central nervous system (CNS) specialist backed by Bain Capital, has entered into...

Company Drug

BeiGene’s Sonrotoclax Gains NMPA Priority Review for MCL Treatment

Fineline Cube May 13, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Medical Device

United Imaging Healthcare Gains FDA Approval for uAngio AVIVA Interventional X-ray System

Fineline Cube May 13, 2025

China-based United Imaging Healthcare (UIH, SHA: 688271) announced that it has received marketing approval from...

Policy / Regulatory

Trump Executive Order Seeks to Align US Prescription Drug Prices with Global Standards

Fineline Cube May 13, 2025

U.S. President Donald J. Trump has signed an executive order aimed at aligning prescription drug...

Company Drug

Fosun Pharma’s FCN-159 Granted Breakthrough Therapy Designation for Pediatric LCH

Fineline Cube May 13, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its novel small-molecule...

Company Drug

Merck Sharp & Dohme Launches Recarbrio in China for Bacterial Pneumonia and Infections

Fineline Cube May 13, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official...

Company Deals

Roche Invests $550 Million in Indianapolis Diagnostics Facility for CGM Systems

Fineline Cube May 13, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced plans to invest up to USD 550...

Company Drug

RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints

Fineline Cube May 13, 2025

China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...

Company Deals

Eastenova Biotechnology Makes Hong Kong IPO Debut With Regenerative Medicine Focus

Fineline Cube May 13, 2025

China-based Eastenova (Chengdu) Biotechnology Co., Ltd. this week made an initial public offering (IPO) to...

Company Drug

AstraZeneca’s Trixeo Aerosphere Wins UK Approval for COPD

Fineline Cube May 13, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced this week that it has received marketing...

Company Drug

Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial

Fineline Cube May 13, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Posts pagination

1 … 187 188 189 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.